| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13D/A |
| 13 Nov 2026 |
Form 4: Enright Patrick G, Director
Sold 500,000 shares ($75.2M) |
| 13 Nov 2026 |
Form 4: Longitude Capital Partners V, Llc, 10% owner and 1 other
Sold 500,000 shares ($75.2M) |
| 12 Nov 2026 | 144 |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first oral treatment to receive FDA approval for pattern hair loss in nearly 30 years |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Study ‘302’ Part B Phase 3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss November 2026 NOVEMBER 2026 |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) admini... |
| 13 Oct 2026 | SCHEDULE 13G |
| 03 Sep 2026 |
Form 4: Hollander David, Chief R&D Officer
Received 9,650 shares as a grant or award · Granted 19,300 Stock Option (Right to Buy) |
| 21 Aug 2026 | SCHEDULE 13D/A |
| 21 Aug 2026 |
Form 4: Montanova CAPITAL, Llc, Director and 3 others
Sold 750,000 shares ($80.4M) · Received 300,000 shares by exercise |
| 20 Aug 2026 |
Form 3: Hollander David, Chief R&D Officer
No securities owned |
| 19 Aug 2026 | 144 |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Durso Timothy August, Chief Technical Officer
Received 3,452 shares by exercise or conversion ($42.1K) · Sold 43,500 shares ($4.69M) |
| 18 Aug 2026 |
Form 4: Waldman Reid Alexander, Director
Received 3,452 shares by exercise or conversion ($42.1K) · Sold 67,500 shares ($7.28M) |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 | 144 |
| 14 Aug 2026 | EFFECT |
Loading...